Print selected from Online session20/11/2002

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1612RXD

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Apr 09	BEILSTEIN: Reload and Implementation of a New Subject Area
NEWS 4	Apr 09	ZDB will be removed from STN
NEWS 5	Apr 19	US Patent Applications available in IFICDB, IFIPAT, and IFIUDB
NEWS 6	Apr 22	Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7	Apr 22	BIOSIS Gene Names now available in TOXCENTER
NEWS 8	Apr 22	Federal Research in Progress (FEDRIP) now available
NEWS 9	Jun 03	New e-mail delivery for search results now available
NEWS 10	Jun 10	MEDLINE Reload
NEWS 11	Jun 10	PCTFULL has been reloaded
NEWS 12	Jul 02	FOREGE no longer contains STANDARDS file segment
NEWS 13	Jul 22	USAN to be reloaded July 28, 2002; saved answer sets no longer valid
NEWS 14	Jul 29	Enhanced polymer searching in REGISTRY
NEWS 15	Jul 30	NETFIRST to be removed from STN
NEWS 16	Aug 08	CANCERLIT reload
NEWS 17	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 18	Aug 08	NTIS has been reloaded and enhanced
NEWS 19	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 20	Aug 19	IFIPAT, IFICDB, and IFIUDB have been reloaded
NEWS 21	Aug 19	The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 22	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 23	Sep 03	JAPIO has been reloaded and enhanced
NEWS 24	Sep 16	Experimental properties added to the REGISTRY file
NEWS 25	Sep 16	Indexing added to some pre-1967 records in CA/CAPLUS
NEWS 26	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 27	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 28	Oct 21	EVENTLINE has been reloaded
NEWS 29	Oct 24	BEILSTEIN adds new search fields
NEWS 30	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 31	Oct 25	MEDLINE SDI run of October 8, 2002
NEWS 32	Nov 18	DKILIT has been renamed APOLLIT

NEWS EXPRESS	October 14 CURRENT WINDOWS VERSION IS V6.01, CURRENT MACINTOSH VERSION IS V6.0a(ENG) AND V6.0Ja(JP), AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

Print selected from Online session20/11/2002

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:14:34 ON 20 NOV 2002

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:14:44 ON 20 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 18 NOV 2002 HIGHEST RN 473870-51-8
DICTIONARY FILE UPDATES: 18 NOV 2002 HIGHEST RN 473870-51-8

TSCA INFORMATION NOW CURRENT THROUGH MAY 20, 2002

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf

=>
Uploading 10066503.str

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 15:15:02 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     498 TO ITERATE

100.0% PROCESSED     498 ITERATIONS                                 13 ANSWERS
SEARCH TIME: 00.00.04

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          8622 TO    11298
PROJECTED ANSWERS:               44 TO      476

L2            13 SEA SSS SAM L1

=> s  l1 ful
FULL SEARCH INITIATED 15:15:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -  10264 TO ITERATE

100.0% PROCESSED   10264 ITERATIONS                               191 ANSWERS
SEARCH TIME: 00.00.05

L3           191 SEA SSS FUL L1

=> file uspatall
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   140.28     140.49

FILE 'USPATFULL' ENTERED AT 15:15:34 ON 20 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:15:34 ON 20 NOV 2002
CA INDEXING COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

=> s l3
COMMAND INTERRUPTED
   1 FILES SEARCHED...

If this message appears repeatedly, please notify the Help Desk.
```

Print selected from Online session20/11/2002

Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.

=>

=> s l3
L4 12 L3

=> d abs bib hitstr 1-12

L4 ANSWER 1 OF 12 USPATFULL
AB The present invention describes compounds of formula I: ##STR1##

and pharmaceutically acceptable salts thereof, wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, m and n are as defined in the specification. The compounds of formula I are protein kinase inhibitors and are useful in the treatment of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of Alzheimer's disease, chemotherapy-induced alopecia, and cardiovascular disease.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:251824 USPATFULL
TI Aminothiazole inhibitors of cyclin dependent kinases
IN Kim, Kyoung S., North Brunswick, NJ, UNITED STATES
Kimball, S. David, East Windsor, NJ, UNITED STATES
Cai, Zhen-Wei, Somerville, NJ, UNITED STATES
Rawlins, David B., Morrisville, PA, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Poss, Michael A., Lawrenceville, NJ, UNITED STATES
Webster, Kevin R., Yardley, PA, UNITED STATES
Hunt, John T., Princeton, NJ, UNITED STATES
Han, Wen-Ching, Newtown, PA, UNITED STATES
PI US 2002137778 A1 20020926
AI US 2001-839751 A1 20010420 (9)
RLI Continuation of Ser. No. US 1999-464511, filed on 15 Dec 1999, GRANTED, Pat. No. US 6262096
DT Utility
FS APPLICATION
LREP MARLA J MATHIAS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 46
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 3814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **224436-03-7P**
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 2 OF 12 USPATFULL

AB Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: ##STR1##

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: ##STR2##

where q is 1, 2, or 3, W.sup.3 is --O--; --N(R.sup.9)--; or --OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6) alkyl, --(C.sub.2-C.sub.6) alkenyl, or --(C.sub.2-C.sub.6) alkynyl substituted by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is --O--; --S(.dbd.O).sub.t--, where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--, or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4) alkynyl; --R.sup.16; --OR.sup.16; --S(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.sup.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.16R.sup.16; --NR.sup.12.sub.aC(.dbd.N--

NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17 --S(.dbd.O).sub.pNR.sup.16R.sup.17; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4) alkyl including dimethyl and --(C.sub.1-C.sub.4) alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2) alkoxycarbonyl-, (C.sub.1-C.sub.2) alkylcarbonyl-, or (C.sub.1-C.sub.2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): ##STR3##

or a pharmaceutically acceptable salt thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:206794 USPATFULL
TI Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
IN Magee, Thomas Victor, Mystic, CT, UNITED STATES
Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert James, Mystic, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2002111495 A1 20020815
AI US 2002-62811 A1 20020131 (10)
PRAI US 2001-265240P 20010131 (60)
US 1997-43403P 19970404 (60)
US 1998-105120P 19981021 (60)
DT Utility
FS APPLICATION
LREP PFIZER INC, 150 EAST 42ND STREET, 5TH FLOOR - STOP 49, NEW YORK, NY, 10017-5612
CLMN Number of Claims: 22
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 7710
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **214754-74-2P 214754-75-3P 214754-96-8P 214754-98-0P 214755-00-7P 214755-73-4P 214755-98-3P**
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)
RN 214754-74-2 USPATFULL
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214754-75-3 USPATFULL
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1S)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214754-96-8 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214754-98-0 USPATFULL
CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 214755-00-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(3-pyridinyloxy)-
(9CI) (CA INDEX NAME)



RN 214755-73-4 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-nitrophenoxy)-N-[[4-(2,2,2-
trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-98-3 USPATFULL
CN Propanoic acid, 2,2-dimethyl-, 4-[[[[2-(4-fluorophenoxy)-3-
pyridinyl]carbonyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 3 OF 12 USPATFULL

AB The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-azacycloalkanoylaminothiazole compounds of formula I ##STR1##

or a pharmaceutically acceptable salt thereof, wherein:

R is alkyl, aryl or heteroaryl;

R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each independently hydrogen, alkyl, aryl or heteroaryl;

R.sup.6 and R.sup.7 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy;

R.sup.8 is hydrogen, alkyl, aryl, heteroaryl, CONR.sup.9R.sup.10, COR.sup.11 or COOR.sup.12;

R.sup.9, R.sup.10, R.sup.11 and R.sup.12 are each independently hydrogen, alkyl or aryl;

m equals 0 to 5; and

n equals 0 to 5,

which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention further concerns new key intermediate compounds, a quaternary ammonium salt of formula III' and a 2-oxazolylalkyl derivative of formula IX.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:186294 USPATFULL

TI Process for preparing azacycloalkanoylaminothiazoles

IN Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
Kim, Kyoung S., North Brunswick, NJ, UNITED STATES
Kimball, S. David, East Windsor, NJ, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Salvati, Mark E., Lawrenceville, NJ, UNITED STATES
Sundeen, Joseph E., Yardley, PA, UNITED STATES
Xiao, Hai-Yun, Princeton, NJ, UNITED STATES
Zhao, Rulin, Pennington, NJ, UNITED STATES

PI US 2002099217 A1 20020725

AI US 2002-100129 A1 20020318 (10)

RLI Division of Ser. No. US 2000-746060, filed on 22 Dec 2000, PENDING

Continuation-in-part of Ser. No. US 2000-616627, filed on 26 Jul 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-616629, filed on 26 Jul 2000, GRANTED, Pat. No. US 6214852 Continuation-in-part of Ser. No. US 1999-464511, filed on 15 Dec 1999, GRANTED, Pat. No. US 6262096

DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 51
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 814
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **224436-03-7P**
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 4 OF 12 USPATFULL
AB The present invention relates to new, efficient processes for the preparation of 5-(2-oxazolylalkylthio)-2-arylacetylaminothiazole compounds of formula I: ##STR1##

or a pharmnaceutically acceptable salt thereof, wherein:

R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, R.sup.8, R.sup.9, R.sup.12 and R.sup.13 are each independently hydrogen, alkyl, aryl or heteroaryl;

R.sup.3, R.sup.7, R.sup.10 and R.sup.11 are each independently hydrogen, alkyl, aryl, heteroaryl, halogen, hydroxy or alkoxy; and

X is CH or N,

which are novel, potent inhibitors of cyclin dependent kinases (cdks). The present invention also concerns a new process for the preparation of formylarylacetates and formylarylacetic acids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:141622 USPATFULL
TI Process for preparing arylacetylaminothiazoles

Print selected from Online session20/11/2002

IN Chen, Bang-Chi, Plainsboro, NJ, UNITED STATES
Kim, Kyoung S., North Brunswick, NJ, UNITED STATES
Kimball, S. David, East Windsor, NJ, UNITED STATES
Misra, Raj N., Hopewell, NJ, UNITED STATES
Sundeen, Joseph E., Yardley, PA, UNITED STATES
Zhao, Rulin, Pennington, NJ, UNITED STATES
PI US 2002072609 A1 20020613
AI US 2002-67723 A1 20020205 (10)
RLI Division of Ser. No. US 2000-746059, filed on 22 Dec 2000, PENDING Continuation-in-part of Ser. No. US 2000-616627, filed on 26 Jul 2000, ABANDONED Continuation-in-part of Ser. No. US 2000-616629, filed on 26 Jul 2000, PATENTED Continuation-in-part of Ser. No. US 1999-464511, filed on 15 Dec 1999, PATENTED
DT Utility
FS APPLICATION
LREP STEPHEN B. DAVIS, BRISTOL-MYERS SQUIBB COMPANY, PATENT DEPARTMENT, P O BOX 4000, PRINCETON, NJ, 08543-4000
CLMN Number of Claims: 50
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 668
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **224436-03-7P**
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 12 USPATFULL
AB A compound of formula (I) wherein m, n, o, p, q, r, A, B, D, E, R.sup.1, R.sup.2,R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are as defined in the description, useful in the treatment of respiratory, allergic, rheumatoid, body weight regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, weight control, rheumatoid arthritis, cachexia, crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2002:95811 USPATFULL
TI Nicotinamide derivatives
IN Marfat, Anthony, Mystic, CT, United States
Chambers, Robert J., Mystic, CT, United States
Watson, John W., Ledyard, CT, United States
Cheng, John B., Waterford, CT, United States
Duplantier, Allen J., Ledyard, CT, United States
Kleinman, Edward F., Pawcatuck, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6380218 B1 20020430
WO 9845268 19981015
AI US 1999-308956 19990527 (9)
WO 1998-IB315 19980310
19990527 PCT 371 date
PRAI US 1997-43403P 19970404 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Rotman, Alan L.; Assistant Examiner: Desai, Rita
LREP Richardson, Peter C., Ginsburg, Paul H., Speer, Raymond M.
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 6569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **214754-74-2P 214754-75-3P 214754-96-8P**
214754-98-0P 214755-00-7P 214755-73-4P
214755-98-3P
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)
RN 214754-74-2 USPATFULL
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 214754-75-3 USPATFULL
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1S)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 214754-96-8 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-pyridinyloxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214754-98-0 USPATFULL
CN 3-Pyridinecarboxamide, N-[[4-(difluoromethoxy)phenyl]methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 214755-00-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(3-pyridinyloxy)- (9CI) (CA INDEX NAME)



RN 214755-73-4 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-nitrophenoxy)-N-[[4-(2,2,2-trifluoroethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 214755-98-3 USPATFULL
CN Propanoic acid, 2,2-dimethyl-, 4-[[[[2-(4-fluorophenoxy)-3-pyridinyl]carbonyl]amino]methyl]phenyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 12 USPATFULL
AB Phenylalanine derivatives of formula (1) are described: ##STR1##

wherein

R is a carboxylic acid or a derivative thereof;

L.sup.1 is a linker atom or group;

Het is an optionally substituted heteroaromatic group;

and the salts, solvates, hydrates and N-oxides thereof.

The compounds are able to inhibit the binding of alpha4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:61291 USPATFULL
TI Phenylalanine derivatives
IN Head, John Clifford, Maidenhead, UNITED KINGDOM
Archibald, Sarah Catherine, Maidenhead, UNITED KINGDOM
Warrellow, Graham John, Northwood, UNITED KINGDOM
Porter, John Robert, Chinnor, UNITED KINGDOM
PA Celltech Therapeutis, Limited (non-U.S. corporation)
PI US 2002035127 A1 20020321
AI US 2001-964161 A1 20010926 (9)
RLI Continuation of Ser. No. US 1999-237060, filed on 26 Jan 1999, PENDING
PRAI GB 1998-1674 19980127
GB 1998-26669 19981203
DT Utility
FS APPLICATION
LREP Francis A. Paintin, Esq., WOODCOCK WASHBURN KURTZ MACKIEWICZ & NORRIS, 46th Floor, One Liberty Place, Philadelphia, PA, 19103
CLMN Number of Claims: 14
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2236
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **232617-62-8P 232617-65-1P 232617-86-6P 232618-01-8P**
(prepn. of phenylalanine derivs. as pharmaceutical agents)
RN 232617-62-8 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 232617-65-1 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(4-methylphenyl)thio]-3-

pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-86-6 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[(2-phenoxy-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232618-01-8 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT **232617-27-5P 232617-57-1P**
(prepn. of phenylalanine derivs. as pharmaceutical agents)
RN 232617-27-5 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-57-1 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 7 OF 12 USPATFULL

AB Phenylalanine derivatives of formula (1) are described: ##STR1##

wherein

R is a carboxylic acid or a derivative thereof;

L.sup.1 is a linker atom or group;

Het is an optionally substituted heteroaromatic group;

and the salts, solvates, hydrates and N-oxides thereof.

The compounds are able to inhibit the binding of alpha4 integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 2001:226629 USPATFULL
TI Phenylalanine derivatives
IN Head, John Clifford, Maidenhead, United Kingdom
Archibald, Sarah Catherine, Maidenhead, United Kingdom
Warrellow, Graham John, Northwood, United Kingdom
Porter, John Robert, Chinnor, United Kingdom
PA Celltech Therapeutics Limited, United Kingdom (non-U.S. corporation)
PI US 6329372 B1 20011211
AI US 1999-237060 19990126 (9)
PRAI GB 1998-1674 19980127
GB 1998-26669 19981203
DT Utility
FS GRANTED
EXNAM Primary Examiner: Shah, Mukund J.; Assistant Examiner: Truong, Tamthom N.
LREP Woodcock Washburn Kurtz Mackiewicz & Norris LLP
CLMN Number of Claims: 19
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2431
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **232617-62-8P 232617-65-1P 232617-86-6P**
232618-01-8P
(prepn. of phenylalanine derivs. as pharmaceutical agents)

RN 232617-62-8 USPATFULL

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 232617-65-1 USPATFULL

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(4-methylphenyl)thio]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-86-6 USPATFULL

CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[(2-phenoxy-3-pyridinyl)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232618-01-8 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT **232617-27-5P 232617-57-1P**
(prepn. of phenylalanine derivs. as pharmaceutical agents)
RN 232617-27-5 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 232617-57-1 USPATFULL
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)sulfonyl]-3-pyridinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 8 OF 12 USPATFULL
AB Compounds of the formula ##STR1##

and pharmaceutically acceptable salts thereof.

R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl;

R.sub.3 is aryl or heteroaryl

R.sub.4 is alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl;

m is an integer of 0 to 2; and

n is an integer of 1 to 3.

The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2001:112361 USPATFULL
TI Aminothiazole inhibitors of cyclin dependent kinases
IN Kim, Kyoung S., North Brunswick, NJ, United States
Kimball, S. David, East Windsor, NJ, United States
Cai, Zhen-wei, Somerville, NJ, United States
Rawlins, David B., Morrisville, PA, United States
Misra, Raj N., Hopewell, NJ, United States
Poss, Michael A., Lawrenceville, NJ, United States
Webster, Kevin R., Yardley, PA, United States

Hunt, John T., Princeton, NJ, United States
Han, Wen-Ching, Newtown, PA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6262096 B1 20010717
AI US 1999-464511 19991215 (9)
RLI Continuation-in-part of Ser. No. US 1998-176239, filed on 21 Oct 1998, now patented, Pat. No. US 6040321
DT Utility
FS GRANTED
EXNAM Primary Examiner: Gerstl, Robert
LREP Patel, Rena
CLMN Number of Claims: 1
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2451
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **224436-03-7P**
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 9 OF 12 USPATFULL
AB Compounds of the formula ##STR1## and pharmaceuticaly acceptable salts thereof. As used in formula I, and throughout the specification, the symbols have the following meanings:

R.sub.1 and R.sub.2 are independently hydrogen, fluorine or alkyl;

R.sub.3 is aryl or heteroaryl

R.sub.4 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylalkyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl, heterocycloalkylalkyl; or

CO-alkyl,

CONH-alkyl,

COO-alkyl,

SO.sub.2 -alkyl,

C(NCN)NH-alkyl,

C(NNO.sub.2)NH-alkyl,

C(NH)NH-alkyl,

C(NH)NHCO-alkyl,

C(NOR.sub.6)NH-alkyl,

R.sub.5 is hydrogen or alkyl;

R.sub.6 is hydrogen, alkyl, cycloalkyl, aryl, cycloalkylakyl, arylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

m is an integer of 0 to 2; and

n is an integer of 1 to 3.

The compounds of formula I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example, cancer, inflammation and arthritis. They may also be useful in the treatment of neurodegenerative diseases such as Alzheimer's disease, cardiovascular diseases, viral diseases and fungal diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2000:34567 USPATFULL
TI Aminothiazole inhibitors of cyclin dependent kinases
IN Kim, Kyoung S., North Brunswick, NJ, United States
Kimball, S. David, East Windsor, NJ, United States
Cai, Zhen-wei, Somerville, NJ, United States
Rawlins, David B., Morrisville, PA, United States
Misra, Raj N., Hopewell, NJ, United States
Poss, Michael A., Lawrenceville, NJ, United States
Webster, Kevin R., Yardley, PA, United States
Hunt, John T., Princeton, NJ, United States
Han, Wen-Ching, Newtown, PA, United States
PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)
PI US 6040321 20000321
AI US 1998-176239 19981021 (9)
PRAI US 1997-65195P 19971112 (60)
DT Utility
FS Granted
EXNAM Primary Examiner: Gerstl, Robert
LREP Marenberg, Barry J.
CLMN Number of Claims: 45
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 2638
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **224436-03-7P**
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 USPATFULL
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



L4 ANSWER 10 OF 12 USPATFULL

AB Certain N-substituted nicotinamide compounds having formula (I) below ##STR1## and pharmaceutically acceptable acid addition salts thereof wherein R.sup.1 is 1-piperidyl, 1-(3-indolyl)ethyl, C.sub.1-4 alkyl, phenyl, 1-(1-phenylethyl), benzyl or mono-substituted benzyl wherein the substituent is methyl, methoxy, chloro or fluoro; and R.sup.2 is bicyclo[2.2.1]hept-2-yl or ##STR2## wherein Y is hydrogen, fluoro or chloro; and X is hydrogen, fluoro, chloro, methoxy, trifluoromethyl, cyano, carboxy, carbo (C.sub.1-4 alkoxy), methylcarbamoyl or dimethylcarbamoyl function as selective inhibitors of calcium-independent phosphodiesterase and are useful as antidepressants.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 89:72144 USPATFULL

TI Antidepressant N-substituted nicotinamide compounds

IN Saccomano, Nicholas A., Ledyard, CT, United States
Vinick, Fredric J., Waterford, CT, United States

PA Pfizer Inc., New York, NY, United States (U.S. corporation)

PI US 4861891 19890829

AI US 1988-238951 19880831 (7)

DT Utility

FS Granted

EXNAM Primary Examiner: Schwartz, Richard A.

LREP Richardson, Peter C., Lumb, J. Trevor, Frost, Albert E.

CLMN Number of Claims: 5

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 748

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **125038-53-1P**
(prepn. of, as antidepressant)

RN 125038-53-1 USPATFULL

CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 11 OF 12 USPATFULL

AB New compounds having the formula ##STR1## in which n is 0 or 1; X is halogen, C.sub.1 -C.sub.3 alkyl, trifluoromethyl or carboethoxy; Y and Z are independently hydrogen, lower alkyl, halo-lower alkyl, thio(halo-lower alkyl), lower alkoxy, nitro, cyano or halogen; provided that:

if X is carboethoxy, Z in halogen and Y is hydrogen or halogen; and

if Y and Z are both halogen, X is halogen, trifluoromethyl or carboethoxy.

These compounds have been found to exhibit herbicidal properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 82:20341 USPATFULL

TI N-Aryl, 2-phenoxy nicotinamide compounds and the herbicidal use thereof

IN Gutman, Arnold D., Berkeley, CA, United States

PA Stauffer Chemical Company, Westport, CT, United States (U.S. corporation)

PI US 4327218 19820427

AI US 1980-210990 19801128 (6)

RLI Division of Ser. No. US 1979-80971, filed on 1 Oct 1979, now patented, Pat. No. US 4270946

DT Utility

FS Granted

EXNAM Primary Examiner: Mills, Catherine L.

LREP Ackerman, Joel G.

CLMN Number of Claims: 52

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 631

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT **78863-50-0P 78863-53-3P 78863-72-6P**
78863-81-7P 78894-66-3P
(prepn. and herbicidal activity of)

RN 78863-50-0 USPATFULL

CN 3-Pyridinecarboxamide, 2-[3-(trifluoromethyl)phenoxy]-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78863-53-3 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78863-72-6 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 78863-81-7 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-bromophenoxy)-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78894-66-3 USPATFULL
CN 3-Pyridinecarboxamide, N-(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenoxy]-
(9CI) (CA INDEX NAME)





L4 ANSWER 12 OF 12 USPATFULL
AB New compounds having the formula ##STR1## in which n is 0 or 1; X is halogen, C.sub.1 -C.sub.3 alkyl, trifluoromethyl or carboethoxy; Y and Z are independently hydrogen, lower alkyl, halo-lower alkyl, thio(halo-lower alkyl), lower alkoxy, nitro, cyano or halogen; provided that:

if X is carboethoxy, Z is halogen and Y is hydrogen or halogen; and

if Y and Z are both halogen, X is halogen, trifluoromethyl or carboethoxy.

These compounds have been found to exhibit herbicidal properties.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 81:30138 USPATFULL
TI N-Aryl,2-phenoxy nicotinamide compounds and the herbicidal use thereof
IN Gutman, Arnold D., Berkeley, CA, United States
PA Stauffer Chemical Company, Westport, CT, United States (U.S. corporation)
PI US 4270946 19810602
AI US 1979-80971 19791001 (6)
DT Utility
FS Granted

EXNAM Primary Examiner: Lee, Mary C.
LREP Ackerman, Joel G.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1,12
DRWN No Drawings
LN.CNT 569
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **78863-50-0P 78863-53-3P 78863-72-6P**
78863-81-7P 78894-66-3P
(prepn. and herbicidal activity of)
RN 78863-50-0 USPATFULL
CN 3-Pyridinecarboxamide, 2-[3-(trifluoromethyl)phenoxy]-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78863-53-3 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78863-72-6 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





RN 78863-81-7 USPATFULL
CN 3-Pyridinecarboxamide, 2-(3-bromophenoxy)-N-[3-[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





RN 78894-66-3 USPATFULL
CN 3-Pyridinecarboxamide, N-(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)





=>
=> file caplus
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION

Print selected from Online session20/11/2002

FULL ESTIMATED COST 112.73 253.22

FILE 'CAPLUS' ENTERED AT 15:36:16 ON 20 NOV 2002
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 20 Nov 2002 VOL 137 ISS 21
FILE LAST UPDATED: 19 Nov 2002 (20021119/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> s l3
L5 18 L3

=> d abs bib fhitstr 1-18.

L5 ANSWER 1 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB Title compds. compds. I [wherein p = 0-1, provided that when p = 0, n = 2; m = 1-3; n = 1-2; W1 and W2 = independently O, S(O)0-2, or NR3; Y = =C(R1a) or N(O)0-1; R1a = H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, fluoroalkoxy, OR16, or (un)substituted carbamoyl; RA and RB = independently H, F, CF3, or (un)substituted (cyclo)alkyl, Ph, or benzyl; or CRARB = spiro moiety; RC and RD = the same as RA and RB except that one of them must be H; R1 and R2 = independently H, F, Cl, CN, NO2, (fluoro)alkyl, alkynyl, OR16, or (un)substituted carbamoyl; R3 = H, alkyl, Ph, benzyl, or OR16; R4, R5 and R6 = independently H, F. Cl, alkynyl, R16, OR16, SO0-2R16, COR16, CO2R16, OCOR16, CN, NO2, (un)substituted carbamoyl(oxy), ureido, carboximidoyl, aryl, heterocyclyl, etc.; or R5 and R6 taken together with the atoms to which they are attached = (hetero)cyclyl; J1 and J2 = independently (un)substituted, (un)satd. monocyclic or fused polycyclic ring; D = (un)substituted carboxy, carbamoyl, acyl, hydroxy(alkyl), cyano(alkyl), etc.; R16 = H or (un)substituted (cyclo)alkyl, alkenyl, Ph, benzyl, or pyridyl] were prepd. as inhibitors of PDE4 (no data). For example, 2-(benzo[1,3]dioxol-5-yloxy)nicotinic acid was coupled with (4-aminomethyl-3-fluorophenoxy)acetic acid Me ester in the presence of 1-hydroxybenzotriazole.bul.H2O and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide.bul.HCl in DMF/CH2Cl2 to give the pyridinecarboxamide II (R = Me) in 38% yield. Sapon. using aq. LiOH in THF and MeOH afforded the desired acid II (R = OH) in 21% yield. I are useful in the treatment of diseases regulated by the activation and degranulation of eosinophils, esp. asthma, chronic bronchitis, and chronic obstructive pulmonary disease (no data). In addn., I may be used in combination therapy with a wide variety of other therapeutic agents.

AN 2002:594842 CAPLUS

DN 137:154859

TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert James; Magee, Thomas Victor; Marfat, Anthony
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 285 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002060896	A1	20020808	WO 2001-IB2726	20011224

PI
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRAI US 2001-265304P P 20010131
OS MARPAT 137:154859
IT **445294-90-6P**
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(PDE4 isoenzyme inhibitor; prepn. of carbamoyl-substituted pyridinyl aryl ether derivs. as inhibitors of PDE4 isoenzymes)
RN 445294-90-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[[4-[(1R)-2-amino-1-methyl-2-oxoethoxy]-2-fluorophenyl]methyl]-2-(1,3-benzodioxol-5-yloxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Title compds. [I; p, q = 0, 1; m = 0-2; n = 1, 2; A = CO2R7, CONR9CO2R7, CONR7R9, OP(O)(OH)2, SO3H, acylsulfonamido, etc.; W = O, S, SO, SO2, NR3; Y = N, NO, CR11; R1, R2 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, etc.; R3 = H, alkyl, Ph, PhCH2, etc.; R4-R6 = H, F, Cl, alkynyl, cyano, NO2, etc.; R7 = H, (substituted) alkyl, alkenyl, alkynyl; R9 = H, alkyl, cycloalkyl, Ph, PhCH2, pyridyl, etc.; R11 = H, F, Cl, cyano, NO2, alkyl, alkynyl, fluoroalkyl, fluoroalkoxy, etc.; Ra, Rb = H, F, CF3, alkyl, (substituted) cycloalkyl, Ph, PhCH2; B1, B2 = 3-7 membered (hetero)cyclyl, 7-12 membered poly(hetero)cyclyl; pairs of variables may form rings; with provisos], were prepd. (no data). Thus, Me 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionate was suspended in Me3COH. Aq. NaOH was added to the suspension, and the reaction mixt. was refluxed 1 h to give 2-[4-[[[2-(benzo[1,3]dioxol-5-yloxy)pyridine-3-carbonyl]amino]methyl]phenyl]-2-methylpropionic acid.

AN 2002:591707 CAPLUS

DN 137:140509

TI Preparation of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isozymes

IN Chambers, Robert J.; Magee, Thomas V.; Marfat, Anthony

PA Pfizer Products Inc., USA

SO Eur. Pat. Appl., 180 pp.
CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1229034	A1	20020807	EP 2002-250202	20020111
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002111495	A1	20020815	US 2002-62811	20020131
	BR 2002000250	A	20021008	BR 2002-250	20020131
PRAI	US 2001-265240P	P	20010131		
	US 1997-43403P	P	19970404		
	US 1998-105120P	P	19981021		

OS MARPAT 137:140509

IT **444807-21-0P**
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(claimed compd.; prepn. of nicotinamides and mimetics as inhibitors of phosphodiesterase IV isoenzymes)

RN 444807-21-0 CAPLUS

CN Benzeneacetic acid, 4-[[[[2-(1,3-benzodioxol-5-yloxy)-3-pyridinyl]carbonyl]amino]methyl]-3-methoxy-.alpha.,.alpha.-dimethyl- (9CI) (CA INDEX NAME)



RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB Title compds. I [wherein W = CH2 or CH2CH2; R3 = H, alkyl, or (un)substituted Ph; R3a = H or alkyl; provided that R3 and R3a cannot both be H and that when R3 = (un)substituted Ph, then R3a = H; X = halo, NH2, alkyl, alkenyl, heteroaryl, CH2OR6, CH2NR6R6a, CH2SR6, CH2CH2CO2R6, or (un)substituted aryl, or (hetero)arylalkyl; R6 = H, (cyclo)alkyl, alkenyl, benzyl, or (un)substituted Ph; R6a = H or alkyl; Y = O or S; R5 = H, alkyl, or NH2; and pharmaceutically acceptable salts, esters, amides, and prodrugs thereof] were prepd. and formulated as farnesyl transferase enzyme inhibitors. For example, coupling of 5-chloromethyl-6-hydroxy-2,3,4-trihydronaphthalen-1-one with thiophenol using diisopropylamine in THF (58%), followed by addn. of (R)-2-imidazol-1-yl-1-phenylethanol in the

presence of PPh3 and di-Et azodicarboxylate in THF (31%), gave II. The latter inhibited farnesyl protein transferase (FPT) with IC50 of 0.3 nM. I are useful for treating and preventing uncontrolled or abnormal proliferation of tissues, such as cancer, atherosclerosis, restenosis, and psoriasis (no data).

AN 2001:780862 CAPLUS
DN 135:331423
TI Preparation of 5-substituted tetralones as inhibitors of ras farnesyl transferase for treatment of proliferative diseases
IN Denny, William Alexander; Hutchings, Richard H.; Johnson, Douglas S.; Kaltenbronn, James Stanley; Lee, Ho Huat; Leonard, Daniele Marie; Milbank, Jared Bruce John; Repine, Joseph Thomas; Rewcastle, Gordon William; White, Andrew David
PA Warner-Lambert Co., USA
SO PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001079180	A2	20011025	WO 2001-US12490	20010416
WO 2001079180	A3	20020523		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI US 2000-197485P P 20000417
OS MARPAT 135:331423
IT **368881-18-9P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of 5-substituted tetralones as Ras farnesyl transferase inhibitors for treatment of proliferative diseases, such as cancer, atherosclerosis, restenosis, and psoriasis)
RN 368881-18-9 CAPLUS
CN 3-Pyridinecarboxamide, 2-phenoxy-N-[5,6,7,8-tetrahydro-2-[(1S)-2-(1H-imidazol-1-yl)-1-phenylethoxy]-5-oxo-1-naphthalenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 4 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB The title compds. I [R1, R2 = H, F, alkyl; R3 = aryl, heteroaryl; R4 = alkyl, cycloalkyl, aryl, etc.; R5 = H, alkyl; m = 0-2; n = 1-3] were prepd. I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis. E.g., a multi-step synthesis of N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide II which showed IC50 of < 50 .mu.M against cdc2/cyclin B1 kinase, against cdk2/cyclin E kinase, and against cdk4/cyclin D1 kinase, was given.

AN 2001:521913 CAPLUS
DN 135:107323
TI Preparation of aminothiazole inhibitors of cyclin dependent kinases
IN Kim, Kyoung S.; Kimball, S. David; Cai, Zhen-wei; Rawlins, David B.; Misra, Raj N.; Poss, Michael A.; Webster, Kevin R.; Hunt, John T.; Han, Wen-ching
PA Bristol-Myers Squibb Co., USA
SO U.S., 164 pp., Cont.-in-part of U.S. 6,040,321.

CODEN: USXXAM
DT Patent
LA English
FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6262096 ✓	B1	20010717	US 1999-464511	19991215
	US 6040321 ✓✓	A	20000321	US 1998-176239	19981021
	US 6214852 ✓	B1	20010410	US 2000-616629	20000726
	WO 2001044217	A1	20010621	WO 2000-US33037	20001206
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000016420	A	20020820	BR 2000-16420	20001206
	EP 1240153	A1	20020918	EP 2000-983935	20001206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2001044241	A1	20010621	WO 2000-US33113	20001207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	WO 2001044242	A1	20010621	WO 2000-US33501	20001207
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	BR 2000016424	A	20020820	BR 2000-16424	20001207
	EP 1240165	A1	20020918	EP 2000-982481	20001207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	EP 1240166	A1	20020918	EP 2000-990204	20001207
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2001004639	A1	20010621	US 2000-746059	20001222
	US 6392053	B2	20020521		
	US 2001006976	A1	20010705	US 2000-746060	20001222
	US 6414156	B2	20020702		
	US 2002137778	A1	20020926	US 2001-839751	20010420
	US 2002072609	A1	20020613	US 2002-67723	20020205
	US 2002099217	A1	20020725	US 2002-100129	20020318
	NO 2002002817	A	20020814	NO 2002-2817	20020613
	NO 2002002864	A	20020813	NO 2002-2864	20020614

PRAI US 1997-65195P P 19971112
US 1998-176239 A2 19981021
US 1999-464511 A2 19991215
US 2000-616627 A 20000726
US 2000-616629 A 20000726
WO 2000-US33037 W 20001206
WO 2000-US33113 W 20001207
WO 2000-US33501 W 20001207
US 2000-746059 A3 20001222
US 2000-746060 A3 20001222
OS MARPAT 135:107323
IT **224436-03-7P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)
RN 224436-03-7 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 18 CAPLUS COPYRIGHT 2002 ACS
AB Synthesis of a new N-hydroxysuccinimidyl resin is described and the N-acylation with this resin provides amide products in high yields and excellent purities. This new linker is suitable for combinatorial library synthesis.
AN 2000:431292 CAPLUS
DN 133:164438
TI A new polymer-bound N-hydroxysuccinimidyl active ester linker
AU Shao, Hui; Zhang, Qiang; Goodnow, Robert; Chen, Li; Tam, Steve
CS Department of Discovery Chemistry, Roche Research Center, Hoffmann-La Roche, Inc., Nutley, NJ, 07110, USA
SO Tetrahedron Letters (2000), 41(22), 4257-4260
CODEN: TELEAY; ISSN: 0040-4039
PB Elsevier Science Ltd.
DT Journal
LA English
IT **287945-64-6P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of polymer-bound N-hydroxysuccinimidyl active ester linker for

N-acylation)
RN 287945-64-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[(4-methoxyphenyl)methyl]-2-(4-methylphenoxy)-(9CI) (CA INDEX NAME)



RE.CNT 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB Title compds. [I; n = 0-2; Q = O, S; R1 = H, (substituted) alkyl, alkenyl, alkynyl; R2 = R1, cycloalkyl, cycloalkylalkyl, Ph; R3 = OH, amino NO2, cyano, CO2H, carbamoyl, etc.; R4 = H, cyano, halo, (substituted) alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R5 = cyano, halo, SF5, (substituted) alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R6 = H, cyano, halo, (substituted) alkyl, alkoxy, alkylthio, alkylsulfinyl, alkylsulfonyl; R7 = H, halo, (substituted) alkyl], were prepd. Thus, 1,3-dimethyl-5-aminopyrazole, 2-(3-trifluoromethylphenoxy)nicotinoyl chloride, and Et3N were stirred in PhMe to give 50% N-(1,3-dimethylpyrazol-5-yl)-2-(3-trifluoromethylphenoxy)nicotinamide. The latter was said to show strong herbicidal activity and to be well tolerated by crop plants.
AN 2000:349159 CAPLUS
DN 132:347567

TI Preparation of N-pyrazolylphenoxynicotinic acid (thio)amides as herbicides.
IN Linker, Karl-Heinz; Mueller, Klaus-Helmut; Drewes, Mark Wilhelm; Feucht, Dieter; Pontzen, Rolf; Wetcholowsky, Ingo
PA Bayer A.-G., Germany
SO Ger. Offen., 42 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19854081	A1	20000525	DE 1998-19854081	19981124
WO 2000031066	A1	20000602	WO 1999-EP8659	19991111

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI DE 1998-19854081 A 19981124
OS MARPAT 132:347567
IT **269395-30-4P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of N-pyrazolylphenoxynicotinic acid (thio)amides as herbicides)
RN 269395-30-4 CAPLUS
CN 3-Pyridinecarboxamide, N-[5-(difluoromethoxy)-1,4-dimethyl-1H-pyrazol-3-yl]-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 18 CAPLUS COPYRIGHT 2002 ACS
AB Phenylalanine derivs. 4-[R1(Alk1)rL1s]C6H2RaRb(Alk2)mCHRR2NR3COHet [R is a carboxylic acid or deriv.; R1 = H, OH, alkoxy or optionally substituted cycloaliph., polycycloaliph., heterocycloaliph., polyheterocycloaliph., arom, or heteroarom. group; Alk1 = optionally substituted aliph. or heteroaliph. chain; L1 is a linker atom or group; r, s = 0, 1; Ra, Rb = -L2(CH2)pL3Rcq, where L2, L3 = a covalent bond or linker atom or group; p = 0, 1; q = 1-3; Rc = H, halo, alkyl, OH, alkoxy, etc.; Alk2 = alkylene; m = 0, 1; R2 = H, Me; R3 = H, alkyl; Het is an optionally substituted

heteroarom. group] and their salts, solvates, hydrates and N-oxides were prepd. as pharmaceutical agents. Thus, N-(2-chloronicotinoyl)-N'-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine was prepd. by coupling reaction of N-(3,5-dichloro-4-picolyl)-L-4-aminophenylalanine Me ester with 2-chloronicotinoyl chloride followed by ester hydrolysis. Title compds. were tested for inhibition of integrin-dependent cell adhesion and generally have IC50 values in the .alpha.4.beta.1 and .alpha.4.beta.7 assays of 1.mu.M and below.

AN 1999:487274 CAPLUS
DN 131:116520
TI Preparation of phenylalanine derivatives as pharmaceutical agents
IN Head, John Clifford; Archibald, Sarah Catherine; Warrellow, Graham John; Porter, John Robert
PA Celltech Therapeutics Limited, UK
SO PCT Int. Appl., 65 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9937618	A1	19990729	WO 1999-GB279	19990127
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6329372	B1	20011211	US 1999-237060	19990126
	AU 9924320	A1	19990809	AU 1999-24320	19990127
	EP 1051399	A1	20001115	EP 1999-903798	19990127
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002501051	T2	20020115	JP 2000-528542	19990127
	US 2002035127	A1	20020321	US 2001-964161	20010926
PRAI	GB 1998-1674	A	19980127		
	GB 1998-26669	A	19981203		
	US 1999-237060	A1	19990126		
	WO 1999-GB279	W	19990127		

OS MARPAT 131:116520
IT **232617-62-8P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenylalanine derivs. as pharmaceutical agents)
RN 232617-62-8 CAPLUS
CN L-Tyrosine, O-[(2,6-dichlorophenyl)methyl]-N-[[2-[(2,5-dimethoxyphenyl)thio]-3-pyridinyl]carbonyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The title compds. I [R1, R2 = H, F, alkyl; R3 = aryl, heteroaryl; R4 = H, alkyl, cycloalkyl, aryl, etc.; R5 = H, alkyl; m = 0-2; n = 1-3] were prepd. I are protein kinase inhibitors and are useful in the treatment and prevention of proliferative diseases, for example cancer, inflammation and arthritis (no data). E.g., N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]acetamide was prepd.

AN 1999:325920 CAPLUS

DN 130:352265

TI Preparation of aminothiazole inhibitors of cyclin dependent kinases

IN Kim, Kyoung S.; Kimball, S. David; Poss, Michael A.; Misra, Raj N.; Cai, Zhen-Wei; Rawlins, David B.; Webster, Kevin; Hunt, John T.; Han, Wen-Ching

PA Bristol-Myers Squibb Company, USA

SO PCT Int. Appl., 132 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 9

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9924416	A1	19990520	WO 1998-US23197	19981102

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2309551	AA	19990520	CA 1998-2309551	19981102
	AU 9912955	A1	19990531	AU 1999-12955	19981102
	AU 730607	B2	20010308		
	BR 9814124	A	20001003	BR 1998-14124	19981102
	EP 1042307	A1	20001011	EP 1998-956431	19981102
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2001522842	T2	20011120	JP 2000-520430	19981102
	ZA 9810332	A	20000511	ZA 1998-10332	19981111
	NO 2000002153	A	20000511	NO 2000-2153	20000427
PRAI	US 1997-65195P	P	19971112		
	WO 1998-US23197	W	19981102		

OS MARPAT 130:352265

IT **224436-03-7P**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of aminothiazole inhibitors of cyclin dependent kinases)

RN 224436-03-7 CAPLUS

CN 3-Pyridinecarboxamide, N-[5-[[(5-ethyl-2-oxazolyl)methyl]thio]-2-thiazolyl]-2-phenoxy- (9CI) (CA INDEX NAME)



RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 18 CAPLUS COPYRIGHT 2002 ACS

GI



I

AB Title compds. [I; wherein m is 0 or 1; n is 0 or 1; o is 0-4; p is 0 or 1; q is 0 or 1; r is 0-4; t is 0 or 1; A is oxygen, NH, or sulfur; B is oxygen or NH; D is oxygen, NH, or alkylamino; E is CH2, O, NH, SO, SO2, S; R1 is H, alkyl, cycloalkyl, aryl, etc.; R2,R3 together with attached carbon form carbonyl group or cycloalkyl ring; R2, R3, R4 is independently H, OH, CN, CO2H, alkyl, etc.; R5 is cyclic, bicyclic, aryl; R6, R7 and R8 are each independently H, CN, COOH, NO2, OH, alkyl, etc.] and pharmaceutical compn. are prepd. for the treatment of respiratory, allergic, rheumatoid, body wt. regulation, inflammatory and central nervous system disorders such as asthma, chronic obstructive pulmonary disease, adult respiratory diseases syndrome, shock, fibrosis, pulmonary hypersensitivity, allergic rhinitis, atopic dermatitis, psoriasis, wt. control, rheumatoid arthritis, cachexia, Crohn's disease, ulcerative colitis, arthritic conditions and other inflammatory diseases, depression, multi-infarct dementia and AIDS.

AN 1998:682365 CAPLUS

DN 129:316147

TI Preparation of nicotinamides as PDE4 D isoenzymes inhibitors

IN Marfat, Anthony; Chambers, Robert James; Watson, John Wesley; Cheng, John Bin; Duplantier, Allen Jacob; Kleinman, Edward Fox

PA Pfizer Products Inc., USA

SO PCT Int. Appl., 200 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9845268	A1	19981015	WO 1998-IB315	19980310
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	AU 9862273	A1	19981030	AU 1998-62273	19980310
	AU 738037	B2	20010906		
	EP 971894	A1	20000119	EP 1998-904343	19980310
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
	JP 2000510481	T2	20000815	JP 1998-542528	19980310
	BR 9810733	A	20000912	BR 1998-10733	19980310
	ZA 9802853	A	19991004	ZA 1998-2853	19980403
	US 6380218	B1	20020430	US 1999-308956	19990527
	NO 9904791	A	19991201	NO 1999-4791	19991001

	US 2002111495	A1	20020815	US 2002-62811	20020131
PRAI	US 1997-43403P	P	19970404		
	WO 1998-IB315	W	19980310		
	US 1998-105120P	P	19981021		
	US 2001-265240P	P	20010131		

OS MARPAT 129:316147

IT **214754-74-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of nicotinamides as PDE4 D isoenzymes inhibitors)

RN 214754-74-2 CAPLUS

CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(1R)-1-(4-methoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 18 CAPLUS COPYRIGHT 2002 ACS

GI



I



II



III

AB The title compds. [I; R1 = alkyl; R2 = (halo)alkyl; R3 = H, halo; R4-R6 = H, C1-6 alkyl, C1-4 haloalkyl, etc.; R7, R8 = H, (substituted) alkyl, Ph, R7R8N = 3-9-membered heterocycle] are prepd. and formulated. Pyrazole deriv. II (1.3 g) was stirred with KOH in MeOH at room temp., MeOH was

distd., toluene was added and distd., the remaining solid was heated with 1.0 g chloropyridine deriv. III and 0.01 g CuCl in DMF at 110.degree. to give 0.80 g I (R1 = Me, R2 = 3-CF3, R3-R7 = H, R8 = 6-CH2CF3), which controlled >90% barnyard grass, Setaria viridis, etc. at 2.5 kg/ha.

AN 1996:132822 CAPLUS
DN 124:176091
TI Preparation of (pyridyloxy)pyrazole derivatives as herbicides
IN Morimoto, Katsuyuki; Oonari, Masatoshi; Furusawa, Hiroyuki; Hatanaka, Masataka; Watanabe, Junichi; Kondo, Yasuo; Nawamaki, Tsutomu; Ishikawa, Kimihiro; Shiojima, Kenichi; Nakahira, Kunimitsu
PA Nissan Chemical Ind Ltd, Japan
SO Jpn. Kokai Tokkyo Koho, 30 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 07285962	A2	19951031	JP 1994-81585	19940420

OS MARPAT 124:176091
IT **173946-99-1P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (pyridyloxy)pyrazole derivs. as herbicides)
RN 173946-99-1 CAPLUS
CN 3-Pyridinecarboxamide, N-(2-methoxyphenyl)-2-[[1-methyl-3-(trifluoromethyl)-1H-pyrazol-5-yl]oxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 11 OF 18 CAPLUS COPYRIGHT 2002 ACS
AB A series of substituted 2-phenoxy-N-phenyl-3-pyridinecarboxamides have been prepd. These compds., an important class of bleaching herbicides, appear to be inhibitors of phytoene desaturase. The biol. activity of these compds. have been assessed using the interference of the compds. with photosynthetic pigment biosynthesis in green alga, Scenedesmus obliques, the inhibition of carotenoid synthesis in carrot-cell cultures, Daucus carota, and the bleaching activity against seedlings of the field pansy, Viola arvensis. The activities have been successfully correlated using Hansch-type relations. All three activities have similar structure-activity relations and an active site has been characterized in terms of polar, steric and lipophilic factors. The nature of this site is

speculated upon from this and other evidence.

AN 1992:41260 CAPLUS
DN 116:41260
TI Structure-activity relations. Part 9. The biological activity and mode of action of substituted 2-phenoxy-N-phenylpyridine-3-carboxamides
AU Balasegaram, Thiruchelvi; Bowden, Keith; Pallett, Ken E.; Tomlinson, Ian D.
CS Dep. Chem. Biol. Chem., Univ. Essex, Colchester/Essex, CO4 3SQ, UK
SO Journal of Chemical Research, Synopses (1991), (9), 234
CODEN: JRPSDC; ISSN: 0308-2342
DT Journal
LA English
IT **78894-66-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and herbicidal activity of)
RN 78894-66-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxyphenyl)-2-[3-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)





L5 ANSWER 12 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The synthesis and biol. properties of a series of nicotinamide ethers I (R = Ph, substituted Ph, bicycloheptyl; R1 = Ph, CH2Ph, CH2C6H4R2-4; R2 = F, Me, OMe) are described. I are structurally novel calcium-independent phosphodiesterase inhibitors and they also inhibit the binding of [3H]rolipram to rat brain membranes and reverse reserpine-induced hypothermia in the mouse. Several compds. exhibited potent in vivo activity comparable to the std. agent, rolipram.
AN 1991:61890 CAPLUS
DN 114:61890
TI Nicotinamide ethers: novel inhibitors of calcium-independent phosphodiesterase and [3H]rolipram binding

Print selected from Online session20/11/2002

AU Vinick, Fredric J.; Saccomano, Nicholas A.; Koe, B. Kenneth; Nielsen, Jann A.; Williams, Ian H.; Thadeio, Peter F.; Jung, Stanley; Meltz, Morgan; Johnson, Jonathan, Jr.; et al.
CS Pfizer Cent. Res., Groton, CT, 06340, USA
SO Journal of Medicinal Chemistry (1991), 34(1), 86-9
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 114:61890
IT **125038-53-1P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and calcium-independent phosphodiesterase and rolipram binding inhibitory activity of)
RN 125038-53-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)



L5 ANSWER 13 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



AB The title compds. [I; R1 = 1-piperidyl, 1-(3-indolyl)ethyl, C1-4 alkyl, Ph, PhCH2CH2, (monosubstituted) PhCH2; R2 = bicyclo[2.2.1]hept-2-yl, phenyl group Q; R3 = H, F, Cl, MeO, CF3, CN, CO2H, MeNHCO, Me2NCO, C1-4 carboalkoxy; R4 = H, F, Cl], useful as CNS agents, particularly antidepressants (no data), were prepd. Thus, 2-(4-fluorophenoxy)nicotinic acid (prepn. from 3-FC6H4OH and 2-chloronicotinic acid given) in THF at -5.degree. was treated with N-methylmorpholine and Me2CHCH2OCOCl followed, after 1 h, with tryptamine. The mixt. was stirred 18 h at room temp. to give 52.4% N-[2-(3-indolyl)ethyl]-2-(4-fluorophenoxy)nicotinamide. I are selective inhibitors of Ca-independent c-AMP phosphodiesterase which exhibit biochem. and behavioral profiles similar to those of rolipran with increased duration of action.
AN 1990:76962 CAPLUS
DN 112:76962
TI Preparation of antidepressant N-substituted nicotinamides
IN Saccomano, Nicholas A.; Vinick, Frederic J.
PA Pfizer Inc., USA
SO U.S., 10 pp.

CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4861891	A	19890829	US 1988-238951	19880831
	EP 357316	A1	19900307	EP 1989-308481	19890822
	EP 357316	B1	19930414		
	R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
	AT 88182	E	19930415	AT 1989-308481	19890822
	CA 1329605	A1	19940517	CA 1989-609655	19890829
	DK 8904268	A	19900301	DK 1989-4268	19890830
	FI 8904066	A	19900301	FI 1989-4066	19890830
	NO 8903471	A	19900301	NO 1989-3471	19890830
	JP 02115168	A2	19900427	JP 1989-224342	19890830
	AU 8940913	A1	19900628	AU 1989-40913	19890830
	AU 609329	B2	19910426		
	HU 52058	A2	19900628	HU 1989-4507	19890830
	HU 208120	B	19930830		
	ZA 8906626	A	19910424	ZA 1989-6626	19890830
PRAI	US 1988-238951		19880831		
	EP 1989-308481		19890822		

OS CASREACT 112:76962; MARPAT 112:76962
IT **125038-53-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as antidepressant)
RN 125038-53-1 CAPLUS
CN 3-Pyridinecarboxamide, 2-(4-fluorophenoxy)-N-[(4-methoxyphenyl)methyl]-(9CI) (CA INDEX NAME)



L5 ANSWER 14 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The title derivs. I (R = H, halo, lower alkyl; R1 = H, lower alkyl; X = H, halo, lower alkyl, haloalkyl, NO2, cyano; Q = N-contg. heterocyclic group)

are prepd. A suspension of KH in THF was stirred with 2-amino-5-trifluoromethylpyridine, then the suspension was treated with 2-(3'-trifluoromethylphenoxy)nicotinoyl chloride to give 21% 2-(3'-trifluoromethylphenoxy)-N-(5-trifluoromethyl-2-pyridyl)nicotinamide, which gave 100% control of Scirpus juncoides, Monochoria vaginalis, and Rotala indica at 1 kg/ha in pot expts. without any damage to rice.

AN 1989:553648 CAPLUS
DN 111:153648
TI Phenoxynicotinamide derivatives as herbicides
IN Tanyama, Eiji; Ogasawara, Yoko; Sugaya, Kyoshi
PA Mitsubishi Petrochemical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 01113369	A2	19890502	JP 1987-267383	19871023

OS MARPAT 111:153648
IT **122928-06-7P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of, as herbicide)
RN 122928-06-7 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-methoxy-6-methyl-2-pyrimidinyl)-2-[3-(trifluoromethyl)phenoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I

AB The pre- and early postemergence herbicidal activity of diflufenican (I) a novel herbicide, is reported and attention is drawn to its ability to control important weeds in winter cereals, including Galium aparine, Veronica hederifolia, Veronica persica and Viola arvensis, which are resistant to substituted-urea herbicides. The synthesis of a series of related compds. is described and the relation between structure and activities against a range of plant species is examd. in respect of changes in the Ph, phenoxy and pyridine rings. The design and synthesis of a small no. of compds. combining the best patterns of substitution in each of the rings is described. The resulting optimization of herbicidal activity in the series is reported, together with field trial results comparing the herbicidal efficacy, crop selectivity and soil persistence of the most active structures.

AN 1987:402547 CAPLUS

DN 107:2547

TI Design and synthesis of N-(2,4-difluorophenyl)-2-(3-trifluoromethylphenoxy)-3-pyridinecarboxamide (diflufenican), a novel pre- and early post-emergence herbicide for use in winter cereals

AU Cramp, Michael C.; Gilmour, James; Hatton, Leslie R.; Hewett, Richard H.; Nolan, Christopher J.; Parnell, Edgar W.

CS Ongar Res. Stn., May and Baker Ltd., Ongar/Essex, CM5 0HW, UK

SO Pesticide Science (1987), 18(1), 15-28
CODEN: PSSCBG; ISSN: 0031-613X

DT Journal

LA English

IT **78863-72-6P**
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. and herbicidal activity of)

RN 78863-72-6 CAPLUS

CN 3-Pyridinecarboxamide, 2-(3-chlorophenoxy)-N-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)





L5 ANSWER 16 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI



I



II

AB The title amides (I; R, R1 = H, alkyl, haloalkyl, haloalkylthio, alkoxy, NO2, CN, halo; R2 = halo, alkyl, CF3, CO2Et; n = 0, 1), effective herbicides at 8 lb/acre, were prepd. Thus, 0.05 mol acid II was treated with Et3N.HCl and SOCl2 to give 66.7% acid chloride, which (0.011 mol) was treated with 3-O2NC6H4NH2 and Et3N in PhMe at <35.degree. to give 73.3% I (R = NO2, R1 = H, R2 = CF3, n = 0). Similarly prepd. were 47 addnl. I.
AN 1981:532680 CAPLUS
DN 95:132680
TI N-Aryl-2-phenoxynicotinamide compounds and their herbicidal use
IN Gutman, Arnold D.
PA Stauffer Chemical Co. , USA
SO U.S., 7 pp.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 4270946	A	19810602	US 1979-80971	19791001
	US 4327218	A	19820427	US 1980-210990	19801128
PRAI	US 1979-80971		19791001		

IT **78863-50-0P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(prepn. and herbicidal activity of)
RN 78863-50-0 CAPLUS
CN 3-Pyridinecarboxamide, 2-[3-(trifluoromethyl)phenoxy]-N-[3-

[(trifluoromethyl)thio]phenyl]- (9CI) (CA INDEX NAME)





L5 ANSWER 17 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI For diagram(s), see printed CA Issue.
AB Phenoxynicotinic acid derivs. I [R = 2-(4-cyclohexylphenyl)propoxy, NHC6H4OEt-p, OCH2COC6H4CH2CHMe2-p, 2-[2-(4-benzhydrylpiperazino)ethoxy]ethyl, 3-pyridylmethoxy, 4-(2-thienyl)-2-oxo-1-quinazolinyl, 6-chloro-4-oxo-3-quinazolinyl, .alpha.-ethyl-.alpha.-(1-ethyl-3-pyrrolidinyl)-benzyloxy] were prepd. by treating I (R = Cl) with the appropriate alc. or amine.
AN 1975:31261 CAPLUS
DN 82:31261
TI Derivatives of phenoxynicotinic acids
PA Dynachim S.a.r.l.
SO Fr. Demande, 29 pp.
CODEN: FRXXBL
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI FR 2197872	A1	19740329	FR 1972-31211	19720904
FR 2197872	B1	19760813		

IT **42170-50-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 42170-50-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-ethoxyphenyl)-2-[3-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)





L5 ANSWER 18 OF 18 CAPLUS COPYRIGHT 2002 ACS
GI For diagram(s), see printed CA Issue.
AB The nicotinamide I (R = NHC6H4OEt-p) was prepd. from I (R = Cl) by treating a CHCl3 soln. with equimolar amts. H2NC6H4OEt- p and C5H5N.
AN 1973:442362 CAPLUS
DN 79:42362
TI (Phenoxynicotinamido)phenols and ethers
IN Aries, Robert
SO Fr., 7 pp.
CODEN: FRXXAK
DT Patent
LA French
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2140772	A5	19730119	FR 1971-20548	19710607

IT **42170-50-3P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)
RN 42170-50-3 CAPLUS
CN 3-Pyridinecarboxamide, N-(4-ethoxyphenyl)-2-[3-(trifluoromethyl)phenoxy]-(9CI) (CA INDEX NAME)





=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	79.79	333.01

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-11.15	-11.15

FILE 'STNGUIDE' ENTERED AT 15:37:39 ON 20 NOV 2002

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Nov 15, 2002 (20021115/UP).

=>
Connection closed by remote host